APA (7th ed.) Citation

U, G., RH, F., S, G., C, K., A, K., A, O., . . . C, U. (2024). RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models. Frontiers in pharmacology, 15, 1426446. https://doi.org/10.3389/fphar.2024.1426446

Chicago Style (17th ed.) Citation

U, Grether, et al. "RG7774 (Vicasinabin), an Orally Bioavailable Cannabinoid Receptor 2 (CB2R) Agonist, Decreases Retinal Vascular Permeability, Leukocyte Adhesion, and Ocular Inflammation in Animal Models." Frontiers in Pharmacology 15 (2024): 1426446. https://doi.org/10.3389/fphar.2024.1426446.

MLA (9th ed.) Citation

U, Grether, et al. "RG7774 (Vicasinabin), an Orally Bioavailable Cannabinoid Receptor 2 (CB2R) Agonist, Decreases Retinal Vascular Permeability, Leukocyte Adhesion, and Ocular Inflammation in Animal Models." Frontiers in Pharmacology, vol. 15, 2024, p. 1426446, https://doi.org/10.3389/fphar.2024.1426446.